Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

Authors

  • Ana Luiza de Melo Rodrigues Hospital Erastinho – Department of Pediatric Oncology and Bone Marrow Transplant – Curitiba (PR), Brazil|Universidade Federal do Paraná – Department of Internal Medicine/Hematology – Curitiba (PR), Brazil. https://orcid.org/0000-0002-2346-7194
  • Adriana Seber Hospital Samaritano de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – São Paulo (SP), Brazil|Universidade Federal de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – Pediatric Oncology Institute – São Paulo (SP), Brazil. https://orcid.org/0000-0003-4578-9423
  • Luciana Domingues Grupo de Pesquisa e Assistência ao Câncer Infantil – São Paulo (SP), Brazil. https://orcid.org/0009-0004-4764-1881
  • Victor Gottardello Zecchin Beneficência Portuguesa de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – São Paulo (SP), Brazil. https://orcid.org/0000-0002-9778-3480
  • Maria Lúcia de Martino Lee Beneficência Portuguesa de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – São Paulo (SP), Brazil. https://orcid.org/0009-0000-0464-7969
  • Liane Daudt Universidade Federal do Rio Grande do Sul – Department of Pediatric Oncology and Bone Marrow Transplant – Clinical Hospital – Porto Alegre (RS), Brazil. https://orcid.org/0000-0001-9495-6932
  • Luiza de Souza Grupo de Pesquisa e Assistência ao Câncer Infantil – Department of Pediatric Oncology and Bone Marrow Transplant – Sorocaba (SP), Brazil. https://orcid.org/0000-0003-1051-8156
  • Adriana Martins de Sousa Universidade Federal do Rio de Janeiro – Department of Pediatric Hematology of the Martagão Gesteira – Institute of Childcare and Pediatrics – Rio de Janeiro (RJ), Brazil. https://orcid.org/0000-0001-8599-2974
  • Antonella Adriana Zanette Hospital Erastinho – Department of Pediatric Oncology and Bone Marrow Transplant – Curitiba (PR), Brazil. https://orcid.org/0009-0002-2511-7208
  • Carla Nolasco Hospital Samaritano de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – São Paulo (SP), Brazil. https://orcid.org/0000-0002-6089-5526
  • Virgínio Climaco Grupo de Pesquisa e Assistência ao Câncer Infantil – Department of Pediatric Oncology and Bone Marrow Transplant – Sorocaba (SP), Brazil. https://orcid.org/0009-0006-6175-5062
  • Ana Carolina Ribeiro Universidade Federal de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – Pediatric Oncology Institute – São Paulo (SP), Brazil. https://orcid.org/0000-0003-2573-4070
  • Thábata Cristina Paradas Moreira da Silva Complexo Hospitalar de Niterói – Department of Pediatric Oncology and Bone Marrow Transplant – Niterói (RJ), Brazil. https://orcid.org/0009-0000-1188-0371
  • Paulo Klinger Hospital AC Camargo – Department of Pediatric Oncology and Bone Marrow Transplant – São Paulo (SP), Brazil. https://orcid.org/0000-0001-6739-062X
  • Cinthya Rocha Real Hospital Português – Department of Pediatric Oncology and Bone Marrow Transplant – Recife (PE), Brazil. https://orcid.org/0009-0002-9314-7046
  • Isis Magalhães Hospital da Criança de Brasília José Alencar – Department of Pediatric Oncology – Brasília (DF), Brazil. https://orcid.org/0000-0003-2447-3753
  • Raul Corrêa Ribeiro St. Jude Children’s Research Hospital – Department of Oncology and Global Pediatric Medicine – Memphis (TN), United States. https://orcid.org/0000-0002-9956-5647

DOI:

https://doi.org/10.46765/2675-374X.2025v6n1e295

Keywords:

Stem Cell Transplantation, Leukemia, Myeloid, Acute, Child, Guideline

Abstract

Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.



References

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006 Nov 25;368(9550):1894–907. https://doi.org/10.1016/S0140-6736(06)69780-8 DOI: https://doi.org/10.1016/S0140-6736(06)69780-8

2. Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, Cortes-Penagos C. Acute myeloid leukemiagenetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 2017; 11(4): 328–39.

3. Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017; 19(1): 1–10. https://doi.org/10.1007/s40272-016-0200-6 DOI: https://doi.org/10.1007/s40272-016-0200-6

4. Sadeghian MH, Rezaei Dezaki Z. Prognostic value of EVI1 expression in pediatric acute myeloid leukemia: a systematic review. Iran J Pathol. 2018;13(3):294–300.

5. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2013;19(7):1021–5. https://doi.org/10.1016/j.bbmt.2013.04.001 DOI: https://doi.org/10.1016/j.bbmt.2013.04.001

6. Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138(12):1009–18. https://doi.org/10.1182/blood.2021011694 DOI: https://doi.org/10.1182/blood.2021011694

7. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011; 155(3): 366–76. https://doi.org/10.1111/j.1365-2141.2011.08851.x DOI: https://doi.org/10.1111/j.1365-2141.2011.08851.x

8. Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jónsson OG, Lausen B, Palle J, Zeller B, Hasle H. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29(3):310–5. https://doi.org/10.1200/jco.2010.30.6829 DOI: https://doi.org/10.1200/JCO.2010.30.6829

9. Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U, Klusmann JH, Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018; 32(10): 2167–77. https://doi.org/10.1038/s41375-018-0071-7 DOI: https://doi.org/10.1038/s41375-018-0071-7

10. de Melo Rodrigues AL, Bonfim C, Seber A, Colturato VAR, Zecchin VG, Nichele S, Daudt LE, Fernandes JF, Vieira AK, Darrigo Junior LG, Gomes AA, Arcuri L, Lenzi L, Picharski GL, Ribeiro RC, de Figueiredo BC. Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil: a multicentric retrospective study. Cell Transplant. 2020;29:963689720949175. https://doi.org/10.1177/0963689720949175 DOI: https://doi.org/10.1177/0963689720949175

11. de Melo Rodrigues AL, Zecchin VG, Lee MLM, Zanette AA, Seber A, Ribeiro RC. Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines. J Bone Transplant Cell Ther. 2021;2(4):139. https://doi.org/10.46765/2675-374X.2021v2n4p139 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p139

12. Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, Takeuchi M, Ohki K, Sanada M, Okubo J, Tomizawa D, Taki T, Shimada A, Sotomatsu M, Horibe K, Taga T, Adachi S, Tawa A, Miyano S, Ogawa S, Hayashi Y. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019;3(20):3157–69. https://doi.org/10.1182/bloodadvances.2019000404 DOI: https://doi.org/10.1182/bloodadvances.2019000404

13. Graff Z, Wachter F, Eapen M, Lehmann L, Cooper T. Navigating treatment options and communication in relapsed pediatric AML. Am Soc Clin Oncol Educ Book. 2024;44(3):e438690. https://doi.org/10.1200/EDBK_438690 DOI: https://doi.org/10.1200/EDBK_438690

14. Dvorak CC, Agarwal R, Dahl GV, Gregory JJ, Feusner JH. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant. 2008;14(7):824–30. https://doi.org/10.1016/j.bbmt.2008.04.015 DOI: https://doi.org/10.1016/j.bbmt.2008.04.015

15. Yamamoto S, Tomizawa D, Kudo K, Hasegawa D, Taga T, Yanada M, Kondo T, Nakazawa Y, Eto T, Inoue M, Kato K, Atsuta Y, Ishida H. Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatr Blood Cancer. 2020;67(5):e28181. https://doi.org/10.1002/pbc.28181 DOI: https://doi.org/10.1002/pbc.28181

16. Miladinovic M, Reinhardt D, Hasle H, Goemans BF, Tomizawa D, Hitzler J, Klusmann JH. Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome. Pediatr Blood Cancer. 2024;71(9):e31141. https://doi.org/10.1002/pbc.31141 DOI: https://doi.org/10.1002/pbc.31141

17. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–93. https://doi.org/10.1182/blood-2011-04-347229 DOI: https://doi.org/10.1182/blood-2011-04-347229

18. Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Rev. 2021;47:100773. https://doi.org/10.1016/j.blre.2020.100773 DOI: https://doi.org/10.1016/j.blre.2020.100773

19. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsky NL; Children’s Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56–62. https://doi.org/10.1182/blood.v97.1.56 DOI: https://doi.org/10.1182/blood.V97.1.56

20. Locatelli F, Masetti R, Rondelli R, Zecca M, Fagioli F, Rovelli A, Messina C, Lanino E, Bertaina A, Favre C, Giorgiani G, Ripaldi M, Ziino O, Palumbo G, Pillon M, Pession A, Rutella S, Prete A. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. Bone Marrow Transplant. 2015;50(2):181–8. https://doi.org/10.1038/bmt.2014.246 DOI: https://doi.org/10.1038/bmt.2014.246

21. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123(10):1615–20. https://doi.org/10.1182/blood-2013-10-535716 DOI: https://doi.org/10.1182/blood-2013-10-535716

22. Simione A, Silva C, Silva Sabaini P, Macedo A, Neves H, Geraldo B, et al. Current use and outcomes of hematopoietic stem cell transplantation: Brazilian Summary Slides–2024. J Bone Marrow Transplant Cell Ther. 2024;5(1):228. https://doi.org/10.46765/2675-374X.2024v5n1p228 DOI: https://doi.org/10.46765/2675-374X.2024v5n1p228

23. Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, Klingebiel T, Kremens B, von der Leyen H, Mauz-Körholz C, Meisel R, Mischke K, Müller I, Niemeyer CM, Peters C, Pohler C, Reinhardt D, Burkhardt B, Schlegel PG, Schulz AS, Schrum J, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34(2):613–24. https://doi.org/10.1038/s41375-019-0584-8 DOI: https://doi.org/10.1038/s41375-019-0584-8

24. Golub TR, Arceci RJ. Acute myelogenous leukemia. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincot; 2002. p. 545–89.

25. Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011;118(2):223–30. https://doi.org/10.1182/blood-2011-01-333070 DOI: https://doi.org/10.1182/blood-2011-01-333070

26. Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015; 33(11): 1265–74. https://doi.org/10.1200/JCO.2014.58.9747 DOI: https://doi.org/10.1200/JCO.2014.58.9747

27. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL. Transplant outcomes for children with t cell acute lymphoblastic leukemia in second remission: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(12):2154–9. https://doi.org/10.1016/j.bbmt.2015.08.023 DOI: https://doi.org/10.1016/j.bbmt.2015.08.023

28. Tavares RCB, Bonfim CS, Seber A, Pereira Lermontov S, Coulturato V, Zecchin VG, Ribeiro L, Fernandes JF, Daudt LE, Grecco CS, Darrigo-Jr LG, Villela N, Nichele S, Gouveia R, Bouzas LF, Hamerschlak N, Vigorito AC, da Silva PM, da Silva PO, da Silva CC, de Souza Fernandez C, Flowers ME, Arcuri LJ. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatr Transplant. 2020;24(7):e13789. https://doi.org/10.1111/petr.13789 DOI: https://doi.org/10.1111/petr.13789

29. Rocha V, Arcuri LJ, Seber A, Colturato V, Zecchin VG, Kuwahara C, Nichele S, Gouveia R, Fernandes JF, Macedo AV, Tavares R, Daudt L, De Souza MP, Darrigo-Jr LG, Villela NC, Mariano LCB, Ginani VC, Zanette A, Loth G, Gomes AA, Hamerschlak N, Flowers ME, Bonfim C; Paediatric Working Group and the Brazil-Seattle Consortium Study Group (GEDECO) of the Brazilian Bone Marrow Transplantation Society (SBTMO). Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. Bone Marrow Transplant. 2021;56(12):3042–8. https://doi.org/10.1038/s41409-021-01453-0 DOI: https://doi.org/10.1038/s41409-021-01453-0

30. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P, Thuret I, Blaise D, Bernaudin F, Jouet JP. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. J Clin Oncol. 1994;12(6):1217–22. https://doi.org/10.1200/JCO.1994.12.6.1217 DOI: https://doi.org/10.1200/JCO.1994.12.6.1217

31. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O’Reilly RJ, Papadopoulos EB. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant. 2007;13(2):235–44. https://doi.org/10.1016/j.bbmt.2006.10.005 DOI: https://doi.org/10.1016/j.bbmt.2006.10.005

32. Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, Shukla N, Khalaf R, O’Reilly RJ, Boulad F. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment related myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012;18(3):473–80. https://doi.org/10.1016/j.bbmt.2011.11.009 DOI: https://doi.org/10.1016/j.bbmt.2011.11.009

33. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F; AIEOP AML Study Group. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170–8. https://doi.org/10.1182/blood-2013-03-491621 DOI: https://doi.org/10.1182/blood-2013-03-491621

34. Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M, Ehlert K, Gruhn B, Greil J, Handgretinger R, Holter W, Klingebiel T, Kremens B, Lang P, Mauz-Körholz C, Meisel R, Müller I, Peters C, Reinhardt D, Sedlacek P, Schulz A, Schuster FR, Schrauder A, Strahm B, Sykora KW, Wössmann W, Zimmermann M, Sauer MG. Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplant. 2013;48(5):651–6. https://doi.org/10.1038/bmt.2012.204 DOI: https://doi.org/10.1038/bmt.2012.204

35. de Berranger E, Cousien A, Petit A, Peffault de Latour R, Galambrun C, Bertrand Y, Salmon A, Rialland F, Rohrlich PS, Vannier JP, Lutz P, Yakouben K, Duhamel A, Bruno B, Michel G, Dalle JH. Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Bone Marrow Transplant. 2014;49(3):382–8. https://doi.org/10.1038/bmt.2013.185 DOI: https://doi.org/10.1038/bmt.2013.185

36. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21(7):1299–307. https://doi.org/10.1016/j.bbmt.2015.03.003 DOI: https://doi.org/10.1016/j.bbmt.2015.03.003

37. Owattanapanich W, Ungprasert P, Wais V, Kungwankiattichai S, Bunjes D, Kuchenbauer F. FLAMSA RIC for stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes: a systematic review and meta-analysis. J Clin Med. 2019;8(9):1437. https://doi.org/10.3390/jcm8091437 DOI: https://doi.org/10.3390/jcm8091437

38. Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. Eur J Haematol. 2016;96(5):475–82. https://doi.org/10.1111/ejh.12615 DOI: https://doi.org/10.1111/ejh.12615

39. Correa A, Martins A, Donatelli A, Santos C, Cardos M, Quintino L, Zamperlini G, Domingues LDS, Sousa AVL, Seber A. Allogeneic hematopoietic stem cell transplants (HSCT) with adapted FLAMSA can cure half of the pediatric patients with refractory acute myelogenous leukemia (AML). Hematol Transfus Cell Ther. 2023;45(Suppl. 4):S544. https://doi.org/10.1016/j.htct.2023.09.1000 DOI: https://doi.org/10.1016/j.htct.2023.09.1000

40. Locatelli F, Pession A, Comoli P, Bonetti F, Giorgiani G, Zecca M, Taibi RM, Mongini ME, Ambroselli F, de Stefano P, Severi F, Paolucci G. Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia. Br J Haematol. 1996;92(1):49–54. https://doi.org/10.1046/j.1365-2141.1996.00276.x DOI: https://doi.org/10.1046/j.1365-2141.1996.00276.x

41. Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W, Friedrich W, Hasle H, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Pession A, Peters C, Schmid HJ, Stary J, Suttorp M, Uderzo C, van’t Veer-Korthof ET, Vossen J, Zecca M, Zimmermann M. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 1997;15(2):566–73. https://doi.org/10.1200/JCO.1997.15.2.566 DOI: https://doi.org/10.1200/JCO.1997.15.2.566

42. Strahm B, Nöllke P, Zecca M, Korthof ET, Bierings M, Furlan I, Sedlacek P, Chybicka A, Schmugge M, Bordon V, Peters C, O’Marcaigh A, de Heredia CD, Bergstraesser E, Moerloose BD, van den Heuvel Eibrink MM, Starý J, Trebo M, Wojcik D, Niemeyer CM, Locatelli F; EWOG-MDS study group. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25(3):455–62. https://doi.org/10.1038/leu.2010.297 DOI: https://doi.org/10.1038/leu.2010.297

43. Jaiswal SR, Zaman S, Chakrabarti A, Sen S, Mukherjee S, Bhargava S, Ray K, O’Donnell PV, Chakrabarti S. Improved outcome of refractory/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor-mobilized donor lymphocyte infusions. Biol Blood Marrow Transplant. 2016;22(10):1867–73. https://doi.org/10.1016/j.bbmt.2016.07.016 DOI: https://doi.org/10.1016/j.bbmt.2016.07.016

44. Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post transplantation cyclophosphamide in younger children. Pediatr Transplant. 2016;20(5):675–82. https://doi.org/10.1111/petr.12724 DOI: https://doi.org/10.1111/petr.12724

45. Lv X, Qi J, Zhou M, Shi B, Cai C, Tang Y, Pan T, Han Y. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multipletreatments network meta-analysis. Crit Rev Oncol Hematol. 2020;150:102944. https://doi.org/10.1016/j.critrevonc.2020.102944 DOI: https://doi.org/10.1016/j.critrevonc.2020.102944

46. Elgarten CW, Arnold DE, Bunin NJ, Seif AE. Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatr Blood Cancer. 2018;65(1):e26726. https://doi.org/10.1002/pbc.26726 DOI: https://doi.org/10.1002/pbc.26726

47. Lawitschka A, Lucchini G, Strahm B, Dalle JH, Balduzzi A, Gibson B, Diaz De Heredia C, Wachowiak J, Dalissier A, Vettenranta K, Yaniv I, Bordon V, Bauer D, Bader P, Meisel R, Peters C, Corbacioglu S; European Society for Blood, Marrow Transplantation (EBMT) Pediatric Diseases Working Party. Pediatric acute graft-versushost disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations. Transpl Int. 2020;33(7):762–72. https://doi.org/10.1111/tri.13601 DOI: https://doi.org/10.1111/tri.13601

48. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ. Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(1):112–8. https://doi.org/10.1016/j.bbmt.2015.08.034 DOI: https://doi.org/10.1016/j.bbmt.2015.08.034

49. Kwon M, Bailèn R, Pascual-Cascón MJ, Gallardo-Morillo AI, García Sola A, Balsalobre P, Solán L, Dorado N, Munoz C, Serrano D, Martínez-Laperche C, Buno I, Anguita J, Díez-Martin JL. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Adv. 2019;3(21):3351–9. https://doi.org/10.1182/bloodadvances.2019000236 DOI: https://doi.org/10.1182/bloodadvances.2019000236

50. Yerushalmi R, Shem-Tov N, Danylesko I, Shouval R, Nagler A, Shimoni A. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Am J Hematol. 2017;92(3):259–68. https://doi.org/10.1002/ajh.24631 DOI: https://doi.org/10.1002/ajh.24631

51. Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, Merli P, Pagliara D, Prete A, Zecca M. Efficacy of two different doses of rabbit anti-Tlymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(8):1126–36. https://doi.org/10.1016/S1470-2045(17)30417-5 DOI: https://doi.org/10.1016/S1470-2045(17)30417-5

52. Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, Brissot E, Bug G, Ciceri F, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Mohty M. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56(1):218–24. https://doi.org/10.1038/s41409-020-01005-y DOI: https://doi.org/10.1038/s41409-020-01005-y

53. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020; 6(12):1890–9. https://doi.org/10.1001/jamaoncol.2020.4600 DOI: https://doi.org/10.1001/jamaoncol.2020.4600

54. Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108(9):2275–88. https://doi.org/10.3324/haematol.2022.281106 DOI: https://doi.org/10.3324/haematol.2022.281106

55. Breviglieri CNM, Gouveia RV, Ginani VC, Santos CN, de Oliveira MRS, Batalha ABW, de Alencar GS, Goto EH, Marques JF, Pupim MPV, Seber A. Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective. Front Oncol. 2025; 15:1540158. https://doi.org/10.3389/fonc.2025.1540158 DOI: https://doi.org/10.3389/fonc.2025.1540158

Downloads

Published

01/08/2026

How to Cite

Rodrigues, A. L. de M., Seber, A., Domingues, L., Zecchin, V. G., Lee, M. L. de M., Daudt, L., … Ribeiro, R. C. (2026). Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 6(1). https://doi.org/10.46765/2675-374X.2025v6n1e295

Issue

Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Pediatric Consensus Updates

License

Copyright (c) 2026 Ana Luiza de Melo Rodrigues, Adriana Seber, Luciana Domingues, Victor Gottardello Zecchin, Maria Lúcia de Martino Lee, Liane Daudt, Luiza de Souza, Adriana Martins de Sousa, Antonella Adriana Zanette, Carla Nolasco, Virgínio Climaco, Ana Carolina Ribeiro, Thábata Cristina Paradas Moreira da Silva, Paulo Klinger, Cinthya Rocha, Isis Magalhães, Raul Corrêa Ribeiro

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

<< < 1 2 3 4 

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.